- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02053194
A Trial to De-prescribe Inappropriate Medications in the Community Dwelling Elderly (D-PRESCRIBE)
January 23, 2018 updated by: Cara Tannenbaum, Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Developing Pharmacist-led Research to Educate and Sensitive Community Residents to the Inappropriate Prescription Burden in the Elderly
The objective of this trial is to test the beneficial effect of a pharmacist-initiated knowledge transfer intervention to both patients and prescribers on the discontinuation of inappropriate prescriptions, compared to usual care.
The investigators hypothesize that the pharmacist-led intervention will reduce inappropriate prescriptions by at least 20% over 6-months compared to usual care.
The intervention consists of simultaneously educating consumers and providing physicians with an evidence-based pharmaceutical opinion on inappropriate prescriptions.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
600
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women 65 years of age and older (no upper age limit)
- Individuals for whom prescription claims derive from only one pharmacy identifier
- Chronic consumption (> 3 month claims) of one of the target inappropriate prescriptions. (benzodiazepine/non benzodiazepine hypnotic, long-acting sulfonylurea oral hypoglycemic agents, anticholinergic agents (in the form of first-generation antihistamines) or Nonsteroidal anti-inflammatory drugs [NSAIDs] )
- Patients who are willing to participate in the study.
Exclusion Criteria:
- A probable diagnosis of dementia (persons without the capacity to provide informed consent), as determined by a) a prescription for memantine or a cholinesterase inhibitor; b) report from a caregiver or family-member; or c) a baseline screening score on the Folstein Mini-Mental State Exam < 24
- Inability to understand and or communicate in English and/or French
- Patients living in a long-term care facility
- Concomitant use of any antipsychotic medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmacist-led educational intervention
Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists.
Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.
|
1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study.
2) Evidence-based pharmaceutical opinions sent to the treating physicians.
|
No Intervention: Control
Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete discontinuation of inappropriate prescriptions.
Time Frame: 6 months
|
Provincial prescription insurance claims will be used to measure whether the inappropriate prescription has been discontinued in the intervention and control group at 6-months.
Prescription data contain information on all dispensed prescriptions including drug name, dispensation date, dosage, drug form, duration and quantity of the drug dispensed, as well as the license number of the physician who wrote the prescription.
Discontinuation of an inappropriate prescription will be defined as the lack of a claims renewal for that medication during a minimum of three or more consecutive months (with no subsequent renewals) during the nine months following receipt of the intervention.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The frequency, timing and type of pharmaceutical opinions sent by the pharmacist to the patient's primary care physician.
Time Frame: 6 months
|
The occurrence and delivery date of any pharmaceutical opinion sent to the patient's physician will be ascertained by the presence of a pharmacist billing claim recorded within 6 months after randomization of pharmacies to the intervention group.
The type of opinion (evidence-based example provided by the research team vs customized by the pharmacist) will be ascertained by obtaining a photocopied paper copy of the pharmaceutical opinion from the patient's pharmacy record at the end of the trial (by law, the pharmacist must keep a copy in the patient's dossier).
The dates of the paper copy will be matched to the date of the billing registered in the billing database to validate that the latter relates to the drug under study.
|
6 months
|
Effect of the pharmaceutical opinion on the prescriber's behaviour.
Time Frame: 6 months
|
Pharmacists will be provided with a "study response card" to accompany any pharmaceutical opinion sent to a physician for study patients with inappropriate prescriptions.
The "response card" will ask the physician to endorse one of the following three options: 1) I agree with the proposed recommendation and have signed the prescription recommendation you have provided to discontinue or substitute the inappropriate prescription 2) I will discuss with the patient at the next visit; or 3) no change required.
The physician will be asked to fax back the response card to the pharmacist.
A copy of all response cards received by the pharmacist will be collected by the research team at the end of the trial.
The pharmacist will also be asked whether the physician acknowledged the pharmaceutical opinion in any other way.
Lack of acknowledgment of the pharmaceutical opinion by the physician will be coded as a non-response.
|
6 months
|
Patient-physician encounters to discuss inappropriate prescriptions.
Time Frame: 6 months
|
Patient visits to their primary care provider within the 6-months post-intervention will be ascertained by physician billing claims.
Visits to physicians where discussions about inappropriate prescriptions occurred will be determined by patient self-report during the 6-month semi-structured telephone follow-up interview by asking whether patients met with their physician to discuss their prescriptions and what happened during these encounters.
We will also query any phone call discussions with physician on this subject and conversations with pharmacists to discuss prescription changes.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in risk perception around inappropriate prescriptions
Time Frame: Baseline, 6 months
|
Baseline and post-intervention evaluation of participant's, pharmacist's and physician's beliefs about the risks associated with certain inappropriate prescriptions, as listed on the Beers Criteria of inappropriate medication in the elderly.
|
Baseline, 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Cara Tannenbaum, MD, MSc, Centre de recherche de l'Institut universitaire de gériatrie de Montréal
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Turner JP, Martin P, Zhang YZ, Tannenbaum C. Patients beliefs and attitudes towards deprescribing: Can deprescribing success be predicted? Res Social Adm Pharm. 2020 Apr;16(4):599-604. doi: 10.1016/j.sapharm.2019.07.007. Epub 2019 Jul 10.
- Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial. JAMA. 2018 Nov 13;320(18):1889-1898. doi: 10.1001/jama.2018.16131.
- Martin P, Tamblyn R, Ahmed S, Benedetti A, Tannenbaum C. A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trial. Trials. 2015 Jun 10;16:266. doi: 10.1186/s13063-015-0791-1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
October 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
January 31, 2014
First Submitted That Met QC Criteria
January 31, 2014
First Posted (Estimate)
February 3, 2014
Study Record Updates
Last Update Posted (Actual)
January 25, 2018
Last Update Submitted That Met QC Criteria
January 23, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CIHR 201303MOP-299872-KTR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Health Behavior
-
Holbaek SygehusRecruitingHealth Behavior | Health Knowledge, Attitudes, Practice | Health-Related Behavior | Health LiteracyDenmark
-
Finnish Institute for Health and WelfareCompletedHealth Behavior | Health Care Utilization | Health Care Seeking BehaviorFinland
-
Basque Health ServiceUnknownHealth Promotion | Health Behavior | Health Education | Patient Education | Counseling | Behavior TherapySpain
-
Research on Healthcare Performance Lab U1290RecruitingStress | Health Behavior | Health-Related BehaviorFrance
-
University Hospital, Basel, SwitzerlandSolidarMed LesothoRecruitingRecruitment | Health Behavior | Motivation | Social Behavior | Health Care Utilization | Consumer Behavior | Health Care Seeking Behavior | Researcher-Subject RelationsLesotho
-
Imperial College LondonRecruitingHealth Attitude | Disease | Cancer | Health Behavior | Health Knowledge, Attitudes, Practice | Health-Related BehaviorUnited Kingdom
-
Azienda Sanitaria Locale CN2 Alba-BraUniversity of Turin, Italy; University of Eastern Piedmont; Eclectica Sas di...CompletedEffectiveness of the Updated Version of the School-based Program Diario Della Salute (DDS-2) (DDS-2)Mental Health Wellness 1 | Health Behavior | Adolescent BehaviorItaly
-
Research on Healthcare Performance Lab U1290RecruitingSedentary Behavior | Sedentary Time | Health Behavior | Health-Related Behavior | Physical InactivityFrance
-
World Health OrganizationLondon School of Hygiene and Tropical Medicine; University of Ghana; Biomedical... and other collaboratorsRecruitingHealth-Related Behavior | Adolescent Behavior | Adolescent Development | Health Care Seeking BehaviorGhana, Tanzania, Zimbabwe
-
Ankara Yildirim Beyazıt UniversityNot yet recruitingHealth Attitude | Health Behavior | Health KnowledgeTurkey
Clinical Trials on Pharmacist-led educational intervention
-
Chettinad Academy of Research and Education (Deemed...Purbanchal UniversityRecruitingHypertension | Type 2 DiabetesNepal
-
Wake Forest University Health SciencesActive, not recruiting
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Not yet recruitingMild Cognitive Impairment | Polypharmacy | Alzheimer's Disease and Related DementiasUnited States
-
Johns Hopkins UniversityNational Institute on Aging (NIA); Kaiser PermanenteCompletedPolypharmacy | Alzheimer Disease and Related DementiasUnited States
-
Zahava Rosenberg-YungerCompletedUncontrolled Asthma
-
Cedars-Sinai Medical CenterNational Institute on Aging (NIA)Active, not recruitingPolypharmacy | Readmission | Nonadherence, PatientUnited States
-
Medical University of South CarolinaNational Institutes of Health (NIH)CompletedCardiovascular Diseases | Diabetes Mellitus | Medication AdherenceUnited States
-
Rutgers, The State University of New JerseyMerck Sharp & Dohme LLC; Thomas Jefferson UniversityCompletedInfectious Disease | Pneumonia, Bacterial | Influenza | Zoster; HerpesUnited States
-
University of DundeeCompleted